Bacterial toxins that modify the actin cytoskeleton
JT Barbieri, MJ Riese, K Aktories - Annual review of cell and …, 2002 - annualreviews.org
▪ Abstract Bacterial pathogens utilize several strategies to modulate the organization of the
actin cytoskeleton. Some bacterial toxins catalyze the covalent modification of actin or the …
actin cytoskeleton. Some bacterial toxins catalyze the covalent modification of actin or the …
IQGAP1: insights into the function of a molecular puppeteer
AM Abel, KM Schuldt, K Rajasekaran, D Hwang… - Molecular …, 2015 - Elsevier
The intracellular spatiotemporal organization of signaling events is critical for normal cellular
function. In response to environmental stimuli, cells utilize highly organized signaling …
function. In response to environmental stimuli, cells utilize highly organized signaling …
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
L Fong, A Hotson, JD Powderly, M Sznol, RS Heist… - Cancer discovery, 2020 - AACR
Adenosine mediates immunosuppression within the tumor microenvironment through
triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this …
triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this …
[HTML][HTML] Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome
C Yang, JR Siebert, R Burns, ZJ Gerbec… - Nature …, 2019 - nature.com
Natural killer (NK) cells are critical to both innate and adaptive immunity. However, the
development and heterogeneity of human NK cells are yet to be fully defined. Using single …
development and heterogeneity of human NK cells are yet to be fully defined. Using single …
[HTML][HTML] Diacylglycerol kinases (DGKs): novel targets for improving T cell activity in cancer
MJ Riese, EK Moon, BD Johnson… - Frontiers in Cell and …, 2016 - frontiersin.org
Diacylglycerol kinases (DGKs) are a family of enzymes that catalyze the metabolism of
diacylglycerol (DAG). Two isoforms of DGK, DGKα, and DGKζ, specifically regulate the pool …
diacylglycerol (DAG). Two isoforms of DGK, DGKα, and DGKζ, specifically regulate the pool …
[HTML][HTML] STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models
W Jing, D McAllister, EP Vonderhaar, K Palen… - … for immunotherapy of …, 2019 - Springer
Pancreatic cancer is characterized by an immune suppressive stromal reaction that creates
a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human …
a barrier to therapy. A murine transgenic pancreatic cancer cell line that recapitulates human …
[PDF][PDF] Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3
V Janzen, HE Fleming, T Riedt, G Karlsson, MJ Riese… - Cell stem cell, 2008 - cell.com
Limited responsiveness to inflammatory cytokines is a feature of adult hematopoietic stem
cells and contributes to the relative quiescence and durability of the stem cell population in …
cells and contributes to the relative quiescence and durability of the stem cell population in …
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
MJ Riese, LCS Wang, EK Moon, RP Joshi… - Cancer research, 2013 - AACR
Recent clinical trials have shown promise in the use of chimeric antigen receptor (CAR)-
transduced T cells; however, augmentation of their activity may broaden their clinical use …
transduced T cells; however, augmentation of their activity may broaden their clinical use …
PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation
E Bobrovnikova-Marjon, D Pytel, MJ Riese… - … and cellular biology, 2012 - Taylor & Francis
The endoplasmic reticulum (ER) resident PKR-like kinase (PERK) is necessary for Akt
activation in response to ER stress. We demonstrate that PERK harbors intrinsic lipid kinase …
activation in response to ER stress. We demonstrate that PERK harbors intrinsic lipid kinase …
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
DL Bajor, R Mick, MJ Riese, AC Huang… - …, 2018 - Taylor & Francis
We report long-term clinical outcomes and immune responses observed from a phase 1 trial
of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with …
of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with …